GlycoMimetics Completes Enrollment of Relapsed/Refractory AML Patient Cohort in Phase 2 Portion of Clinical Trial of GMI-1271
- Clinical trial now fully enrolled with 91 patients: 25 in newly diagnosed arm and 66 in relapsed refractory arm
- Interim data to be presented at ASCO and EHA Meetings showing high remission rates with acceptable tolerability
- Patients with higher levels of novel biomarker were more likely to achieve response when GMI-1271 was added to standard therapy
"Across the two cohorts of this Phase 1/2 clinical trial, we have a
strong sample size of 91 patients and experienced brisk enrollment,
which we feel is indicative of the strong interest that our clinical
investigators have for this novel agent," said
Interim clinical data from the ongoing trial of GMI-1271 will be
presented at the 2017 meetings of the
"The consistency of our data readouts is great news in and of itself,
and the emerging biomarker data is especially encouraging," said
In addition to the ongoing Phase 1/2 trial, clinical investigators are currently evaluating GMI-1271 in an ongoing Phase 1 clinical trial in multiple myeloma. Preclinical data supporting the multiple myeloma study was recently published in an online preview of the journal Leukemia on April 25, 2017. Specifically, the newly published preclinical results indicate that myeloma with higher levels of E-selectin ligands is a more aggressive disease that is more likely to be resistant to bortezomib, which is currently the front-line standard of care The publication reported that in preclinical studies, the combination treatment of GMI-1271 to bortezomib was able to break this chemoresistance and restore sensitivity to bortezomib which led to significant improvement in survival. This preclinical multiple myeloma conclusion supports the clinical findings on the potential biomarker that the Company is presenting at ASCO and EHA next month.
About AML
AML is a cancer of the blood and bone marrow. AML is the most common
type of acute leukemia in adults. The
About
GlycoMimetics is a clinical-stage biotechnology company focused on
cancer and sickle cell disease.
Forward-Looking Statements
This press release contains forward-looking statements regarding
GlycoMimetics' planned activities with respect to the clinical
development of its drug candidate, GMI-1271. Actual results may differ
materially from those indicated by such forward-looking statements as a
result of various important factors, including the availability and
timing of data from ongoing clinical trials, the uncertainties inherent
in the completion of ongoing clinical trials and the initiation of
future clinical trials, whether interim results from a clinical trial
will be predictive of the final results of the trial or results of early
clinical trials will be indicative of the results of future trials,
expectations for regulatory approvals, availability of funding
sufficient for GlycoMimetics' foreseeable and unforeseeable operating
expenses and capital expenditure requirements, other matters that could
affect the availability or commercial potential of GlycoMimetics' drug
candidates and other factors discussed in the "Risk Factors" section of
GlycoMimetics' Annual Report on Form 10-K that was filed with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20170531005760/en/
Investors:
sannes@annesassociates.com
or
Media:
jamielacey@presscommpr.com
Source:
News Provided by Acquire Media